Abstract:Hyperactivation of Wnt signaling is crucial in tumor formation. Fully elucidating the molecular details of how the cancer-specific Wnt signaling pathway is activated or contributes to tumorigenesis will help in determining future treatment strategies. Here, we aimed to explore the contribution of CUEDC2, a novel CUE-domain-containing protein, to the activation of Wnt signaling and the tumorigenesis of triple-negative breast cancer (TNBC) and to determine the underlying mechanisms. TNBC patient samples and disease-free survival (DFS) data were used to determine the association between CUEDC2 and TNBC progression. The effects of CUEDC2 on TNBC were examined in TNBC cells in vitro and in subcutaneous xenograft tumors in vivo. Gene knockdown, immunoprecipitation plus liquid chromatography-tandem mass spectrometry, pull-down, co-immunoprecipitation, localized surface plasmon resonance, and nuclear translocation analysis were used to uncover the mechanisms of CUEDC2 in regulating Wnt signaling and TNBC development. CUEDC2 is sufficient to maintain the hyperactivation of Wnt signaling required for TNBC tumorigenesis. The contribution of CUEDC2 plays a major role in determining the outcome of oncogenic Wnt signaling both in vitro and in vivo. Mechanistically, the CUE domain in CUEDC2 directly bound to the ARM (7-9) domain in beta-catenin, promoted beta-catenin nuclear translocation and enhanced the expression of beta-catenin targeted genes. More importantly, an 11-amino-acid competitive peptide targeting the CUE domain in CUEDC2 blocked the interactions of CUEDC2 and beta-catenin and abrogated the malignant phenotype of TNBC cells in vitro and in vivo. We observed that TNBC patients who exhibited higher levels of CUEDC2 showed marked hyperactivation of the Wnt signaling pathway and poor clinical outcomes, highlighting the clinical relevance of our findings. CUEDC2 promotes TNBC tumor growth by enhancing Wnt signaling through directly binding to beta-catenin and accelerating its nuclear translocation. Targeting the interactions of CUEDC2 and beta-catenin may be a valuable strategy for combating TNBC.

RCC2 promotes breast cancer progression through regulation of Wnt signaling and inducing EMT.

RCC1 functions as a tumor facilitator in clear cell renal cell carcinoma by dysregulating cell cycle, apoptosis, and EZH2 stability

Regulator Of Chromosome Condensation 2 Modulates Cell Cycle Progression, Tumorigenesis, And Therapeutic Resistance

RCC2 Interacts with Small GTPase RalA and Regulates Cell Proliferation and Motility in Gastric Cancer

RCC2 is a novel p53 target in suppressing metastasis

Ott_a_228914 3093..3103

Regulator of Chromosome Condensation 2 Expression Profile in Hepatocellular Carcinoma and Its Potential Link to Clinical Parameters

RCCD1 Promotes Breast Carcinogenesis Through Regulating Hypoxia-Associated Mitochondrial Homeostasis.

A Human Pan-Cancer System Analysis of Regulator of Chromatin Condensation 2

CDK5RAP2 is a Wnt target gene and promotes stemness and progression of oral squamous cell carcinoma

Comprehensive Analysis of the Expression Profile and Clinical Implications of Regulator of Chromosome Condensation 2 in Pan-Cancers

PRMT2 promotes RCC tumorigenesis and metastasis via enhancing WNT5A transcriptional expression

RCCD1 Depletion Attenuates TGF-β-induced EMT and Cell Migration by Stabilizing Cytoskeletal Microtubules in NSCLC Cells.

RCC2 over-expression in tumor cells alters apoptosis and drug sensitivity by regulating Rac1 activation

RCC2 Promotes Proliferation and Radio-Resistance in Glioblastoma Via Activating Transcription of DNMT1.

CUEDC2 Drives -Catenin Nuclear Translocation and Promotes Triple-Negative Breast Cancer Tumorigenesis

Integrative and Comprehensive Pancancer Analysis of Regulator of Chromatin Condensation 1 (RCC1)

E2F1 Promote the Aggressiveness of Human Colorectal Cancer by Activating the Ribonucleotide Reductase Small Subunit M2

CDCA2 Acts As an Oncogene and Induces Proliferation of Clear Cell Renal Cell Carcinoma Cells.

Supplementary Tables 1-3, Supplementary Figures 1-5 from Overexpression of RCC2 Enhances Cell Motility and Promotes Tumor Metastasis in Lung Adenocarcinoma by Inducing Epithelial–Mesenchymal Transition

CDKL2 Promotes Epithelial-Mesenchymal Transition and Breast Cancer Progression